Global
English
Global
English
Global
English
Poland
polski
Czechia
Český
Italy
Italiano
Kazakhstan
Қазақ
Slovakia
Slovenský
Spain
Español
Russia
Pусский
Ukraine
Українськa
Uzbekistan
Ўзбекча
Vietnam
Tiếng việt
x
Information on results RFP 023555 – ACTIVE SUBSTANCE
In connection with the co-financing of the projects:
- Project “Development, clinical confirmation of bioequivalence and implementation of a new generation combination ternary inhalation drug in the systematic therapy of COPD”, contract number 2022/ABM/04/00011 – 00
- Project “Development, clinical confirmation of bioequivalence and implementation of a new generation combination inhaled drug in the systematic therapy of COPD”, contract number 2022/ABM/04/00012 – 00
- Project “Development, clinical confirmation of bioequivalence and implementation of a new generation complex inhaled drug in the systematic therapy of respiratory diseases Asthma and COPD”, contract number 2022/ABM/04/00013 – 00
financed by the State budget from the Medical Research Agency as part of the Competition for the development of innovative solutions in the area of new pharmaceutical forms of medicinal products authorized for marketing, generic drugs and biosimilars ABM/2022/4, pursuant to § 8 sec. 2 point 2) of the co-financing agreement, Adamed Pharma S.A. informs that the contract will be awarded to the following companies that have presented the most advantageous offers:
- INKE
- MELODY